Anti Thymocyte Globulin- Development
Indian Journal of Hematology and Blood Transfusion · 2026-11 · 42 (6) · 2364-2373
DOI: 10.1007/s12288-026-02576-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Hematology and Blood Transfusion, online erschienen am 03.09.2026. Verfasst von Saswata Banerjee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Bharat Serums & Vaccines Limited, Mumbai, India. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Anti thymocyte globulin (ATG) is a polyclonal antibody primarily derived from rabbit, horse, or porcine sources, used to prevent or treat T-cell-mediated rejection, graft-versus-host disease (GVHD), and aplastic anaemia (AA). It has demonstrated efficacy in reducing both acute and chronic GVHD and improving graft survival in hematopoietic stem cell transplantation (HSCT) and solid organ transplant settings without affecting overall survival. Mechanistically, ATG depletes T-cells, modulates myeloid cells via PDL1 induction, and induces immune regulation. Rabbit ATG (rATG) is commonly used in organ transplants and HSCT. Horse or equine ATG (eATG) has proven efficacy in haematological disorders, particularly AA. Indigenous eATG (Thymogam) is widely used as part of immunosuppressive therapy (IST) in AA. Porcine ATG (pATG) is emerging as a therapeutic alternative in AA. Therapeutic drug monitoring (TDM) has potential to improve dosing precision and immune reconstitution. Future directions focus on optimizing dosing, personalization and expanding indications. Manufacturing of ATG is complex process and requires multilevel monitoring and quality control to ensure efficacy and safety of the products for human use. This article aims to summarise the developmental evolution, composition, mechanism of action, overview of clinical uses of ATG, dosing, administration, and monitoring strategies, including the role of TDM and a brief description of the manufacturing process and various quality aspects of ATGs for clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Affairs, Bharat Serums & Vaccines Limited, Mumbai, India.
- Research & Development, Bharat Serums & Vaccines Limited, Mumbai, India.
ORCID-Profile: Saswata Banerjee
Zitieren
APA
Banerjee, S., Manguesh, R., & Murzello, K. (2026). Anti Thymocyte Globulin- Development. Indian Journal of Hematology and Blood Transfusion, 42(6), 2364-2373. https://doi.org/10.1007/s12288-026-02576-4
Vancouver
Banerjee S, Manguesh R, Murzello K. Anti Thymocyte Globulin- Development. Indian Journal of Hematology and Blood Transfusion. 2026;42(6):2364-2373. doi:10.1007/s12288-026-02576-4
BibTeX
@article{Banerjee2026,
author = {Banerjee, Saswata and Manguesh, Rajan and Murzello, Kripa},
title = {Anti Thymocyte Globulin- Development},
journal = {Indian Journal of Hematology and Blood Transfusion},
year = {2026},
volume = {42},
number = {6},
pages = {2364--2373},
doi = {10.1007/s12288-026-02576-4}
}
EUVIMED